Report Information More information from: https ://www.wis eguyreports .com/reports /464953

Lupus Nephritis - Pipeline Review, H1 2016 Report / Search Code: WGR464953

Price

1-user P DF : $ 2000.0

Description:

Publish Date: 13 April, 2016

Site P DF : $ 4000.0

Enterprise P DF : $ 6000.0

Lupus Nephritis - Pipeline Review, H1 2016 Summary Global Markets Direct’s , ‘Lupus Nephritis - Pipeline Review, H1 2016’, provides an overview of the Lupus Nephritis pipeline lands cape. The report provides comprehens ive information on the therapeutics under development for Lupus Nephritis , complete with analys is by s tage of development, drug target, mechanis m of action (MoA), route of adminis tration (RoA) and molecule type. The report als o covers the des criptive pharmacological action of the therapeutics , its complete res earch and development his tory and lates t news and pres s releas es . Additionally, the report provides an overview of key players involved in therapeutic development for Lupus Nephritis and features dormant and dis continued projects . Global Markets Direct’s report features inves tigational drugs from acros s globe covering over 20 therapy areas and nearly 3,000 indications . The report is built us ing data and information s ourced from Global Markets Direct’s proprietary databas es , company/univers ity webs ites , clinical trial regis tries , conferences , SEC filings , inves tor pres entations and featured pres s releas es from company/univers ity s ites and indus try-s pecific third party s ources . Drug profiles featured in the report undergoes periodic review following a s tringent s et of proces s es to ens ure that all the profiles are updated with the lates t s et of information. Additionally, various dynamic tracking proces s es ens ure that the mos t recent developments are captured on a real time bas is . The report helps in identifying and tracking emerging players in the market and their portfolios , enhances decis ion making capabilities and helps to create effective counter s trategies to gain competitive advantage. Note*: Certain s ections in the report may be removed or altered bas ed on the availability and relevance of data. Scope - The report provides a s naps hot of the global therapeutic lands cape of Lupus Nephritis - The report reviews pipeline therapeutics for Lupus Nephritis by companies and univers ities /res earch ins titutes bas ed on information derived from company and indus try-s pecific s ources - The report covers pipeline products bas ed on various s tages of development ranging from pre-regis tration till dis covery and undis clos ed s tages - The report features des criptive drug profiles for the pipeline products which includes , product des cription, des criptive MoA, R& D brief, licens ing and collaboration details & other developmental activities - The report reviews key players involved Lupus Nephritis therapeutics and enlis ts all their major and minor projects - The report as s es s es Lupus Nephritis therapeutics bas ed on drug target, mechanis m of action (MoA), route of adminis tration (RoA) and molecule type - The report s ummarizes all the dormant and dis continued pipeline projects - The report reviews lates t news related to pipeline therapeutics for Lupus Nephritis Reas ons to buy - Gain s trategically s ignificant competitor information, analys is , and ins ights to formulate effective R& D s trategies - Identify emerging players with potentially s trong product portfolio and create effective counter-s trategies to gain competitive advantage - Identify and unders tand important and divers e types of therapeutics under development for Lupus Nephritis - Identify potential new clients or partners in the target demographic - Develop s trategic initiatives by unders tanding the focus areas of leading companies - Plan mergers and acquis itions effectively by identifying key players and it’s mos t promis ing pipeline therapeutics - Devis e corrective meas ures for pipeline projects by unders tanding Lupus Nephritis

pipeline depth and focus of Indication therapeutics - Develop and des ign in-licens ing and out-licens ing s trategies by identifying pros pective partners with the mos t attractive projects to enhance and expand bus ines s potential and s cope - Modify the therapeutic portfolio by identifying dis continued projects and unders tanding the factors that drove them from pipeline Contents:

Table of Contents Table of Contents 2 Lis t of Tables 6 Lis t of Figures 7 Introduction 8 Global Markets Direct Report Coverage 8 Lupus Nephritis Overview 9 Therapeutics Development 10 Pipeline Products for Lupus Nephritis - Overview 10 Pipeline Products for Lupus Nephritis - Comparative Analys is 11 Lupus Nephritis - Therapeutics under Development by Companies 12 Lupus Nephritis - Therapeutics under Inves tigation by Univers ities /Ins titutes 13 Lupus Nephritis - Pipeline Products Glance 14 Late Stage Products 14 Clinical Stage Products 15 Early Stage Products 16 Lupus Nephritis - Products under Development by Companies 17 Lupus Nephritis - Products under Inves tigation by Univers ities /Ins titutes 18 Lupus Nephritis - Companies Involved in Therapeutics Development 19 AbbVie Inc. 19 As ahi Kas ei Pharma Corp. 20 As tellas Pharma Inc. 21 Azano Pharmaceuticals Inc. 22 Boehringer Ingelheim GmbH 23 Bris tol-Myers Squibb Company 24 Deltanoid Pharmaceuticals Inc. 25 F. Hoffmann-La Roche Ltd. 26 FibroStatin SL 27 GlaxoSmithKline Plc 28 HanAll Biopharma Co., Ltd. 29 Invion Limited 30 Kineta, Inc. 31 MedImmune, LLC 32 Omeros Corporation 33 Takeda Pharmaceutical Company Limited 34 Z yrnat Biotherapeutics SL 35 Lupus Nephritis - Therapeutics As s es s ment 36 As s es s ment by Monotherapy Products 36 As s es s ment by Target 37 As s es s ment by Mechanis m of Action 39 As s es s ment by Route of Adminis tration 41 As s es s ment by Molecule Type 43 Drug Profiles 45 abatacept - Drug Profile 45 Product Des cription 45 Mechanis m of Action 45 R& D Progres s 45 anifrolumab - Drug Profile 48 Product Des cription 48 Mechanis m of Action 48 R& D Progres s 48 belimumab - Drug Profile 50 Product Des cription 50 Mechanis m of Action 50 R& D Progres s 50 BI-655064 - Drug Profile 54 Product Des cription 54 Mechanis m of Action 54 R& D Progres s 54 BMS-986147 - Drug Profile 55 Product Des cription 55 Mechanis m of Action 55 R& D Progres s 55 dalazatide - Drug Profile 56 Product Des cription 56 Mechanis m of Action 56 R& D Progres s 56 DP-001 - Drug Profile 58 Product Des cription 58 Mechanis m of Action 58

R& D Progres s 58 Drug to Antagonize Bradykinin Receptor B1 for Lupus Nephritis - Drug Profile 60 Product Des cription 60 Mechanis m of Action 60 R& D Progres s 60 FSMAB-26 - Drug Profile 61 Product Des cription 61 Mechanis m of Action 61 R& D Progres s 61 HL-161 - Drug Profile 62 Product Des cription 62 Mechanis m of Action 62 R& D Progres s 62 INV-103 - Drug Profile 63 Product Des cription 63 Mechanis m of Action 63 R& D Progres s 63 ixazomib citrate - Drug Profile 65 Product Des cription 65 Mechanis m of Action 65 R& D Progres s 65 mizoribine - Drug Profile 69 Product Des cription 69 Mechanis m of Action 69 R& D Progres s 69 Monoclonal Antibody for Lupus Nephritis - Drug Profile 70 Product Des cription 70 Mechanis m of Action 70 R& D Progres s 70 obinutuzumab - Drug Profile 71 Product Des cription 71 Mechanis m of Action 71 R& D Progres s 71 OMS-721 - Drug Profile 75 Product Des cription 75 Mechanis m of Action 75 R& D Progres s 75 P-Dex - Drug Profile 77 Product Des cription 77 Mechanis m of Action 77 R& D Progres s 77 RO-5461111 - Drug Profile 79 Product Des cription 79 Mechanis m of Action 79 R& D Progres s 79 Stem Cell Therapy for Autoimmune Dis eas es - Drug Profile 80 Product Des cription 80 Mechanis m of Action 80 R& D Progres s 80 venetoclax - Drug Profile 81 Product Des cription 81 Mechanis m of Action 81 R& D Progres s 81 voclos porin - Drug Profile 85 Product Des cription 85 Mechanis m of Action 85 R& D Progres s 85 Y-175L - Drug Profile 88 Product Des cription 88 Mechanis m of Action 88 R& D Progres s 88 Z Y-11 - Drug Profile 89 Product Des cription 89 Mechanis m of Action 89 R& D Progres s 89 Lupus Nephritis - Recent Pipeline Updates 90 Lupus Nephritis - Dormant Projects 124 Lupus Nephritis - Dis continued Products 126 Lupus Nephritis - Product Development Miles tones 127 Featured News & Pres s Releas es 127 Mar 29, 2016: Aurinia Announces Res ult from Data and Safety Monitoring Board for Its Phas e 2b Study in Lupus Nephritis - Study to Continue as Planned 127 Mar 02, 2016: Aurina Receives FDA Fas t Track Des ignation for Voclos porin for the Treatment of Lupus Nephritis 127 Feb 08, 2016: Aurinia Announces Preliminary Topline Data From its Open Label Aurion Study in Lupus Nephritis 128 Feb 02, 2016: Deltanoid Pharmaceuticals Announces Appointment of Douglas Jermas ek as Chief Executive Officer 128

Jan 19, 2016: Aurinia Announces Completion of Patient Enrollment in Its Phas e 2B AURA-LV Study in Lupus Nephritis 129 Dec 03, 2015: Ocata’s Hemangio-derived Mes enchymal Cells Pres erve Kidney Function and Extend Lifes pan in Preclinical Model of Lupus Nephritis 130 Nov 24, 2015: Aurinia Pharmaceuticals Announces Outcome from Data and Safety Monitoring Board for Its Phas e 2b Study in Lupus Nephritis - Study to Continue as Planned 130 Nov 10, 2015: Kineta, Seattle Children’s Res earch Ins titute Pres ent New Data Demons trating Pos itive, Predictive Res pons es to Dalazatide In Lupus 131 Aug 24, 2015: Ocata Therapeutics Receives SBIR Grant from NIH to Develop Proprietary Hemangio-derived Mes enchymal Cell Therapy for Lupus Nephritis 132 Jun 17, 2015: ACT Res earch Sugges ts Role for Dalazatide in Blocking T Cells from Patients with Lupus 132 Appendix 134 Methodology 134 Coverage 134 Secondary Res earch 134 Primary Res earch 134 Expert Panel Validation 134 Contact Us 134 Dis claimer 135 Lis t of Tables Number of Products under Development for Lupus Nephritis , H1 2016 10 Number of Products under Development for Lupus Nephritis - Comparative Analys is , H1 2016 11 Number of Products under Development by Companies , H1 2016 12 Number of Products under Inves tigation by Univers ities /Ins titutes , H1 2016 13 Comparative Analys is by Late Stage Development, H1 2016 14 Comparative Analys is by Clinical Stage Development, H1 2016 15 Comparative Analys is by Early Stage Development, H1 2016 16 Products under Development by Companies , H1 2016 17 Products under Inves tigation by Univers ities /Ins titutes , H1 2016 18 Lupus Nephritis - Pipeline by AbbVie Inc., H1 2016 19 Lupus Nephritis - Pipeline by As ahi Kas ei Pharma Corp., H1 2016 20 Lupus Nephritis - Pipeline by As tellas Pharma Inc., H1 2016 21 Lupus Nephritis - Pipeline by Azano Pharmaceuticals Inc., H1 2016 22 Lupus Nephritis - Pipeline by Boehringer Ingelheim GmbH, H1 2016 23 Lupus Nephritis - Pipeline by Bris tol-Myers Squibb Company, H1 2016 24 Lupus Nephritis - Pipeline by Deltanoid Pharmaceuticals Inc., H1 2016 25 Lupus Nephritis - Pipeline by F. Hoffmann-La Roche Ltd., H1 2016 26 Lupus Nephritis - Pipeline by FibroStatin SL, H1 2016 27 Lupus Nephritis - Pipeline by GlaxoSmithKline Plc, H1 2016 28 Lupus Nephritis - Pipeline by HanAll Biopharma Co., Ltd., H1 2016 29 Lupus Nephritis - Pipeline by Invion Limited, H1 2016 30 Lupus Nephritis - Pipeline by Kineta, Inc., H1 2016 31 Lupus Nephritis - Pipeline by MedImmune, LLC, H1 2016 32 Lupus Nephritis - Pipeline by Omeros Corporation, H1 2016 33 Lupus Nephritis - Pipeline by Takeda Pharmaceutical Company Limited, H1 2016 34 Lupus Nephritis - Pipeline by Z yrnat Biotherapeutics SL, H1 2016 35 As s es s ment by Monotherapy Products , H1 2016 36 Number of Products by Stage and Target, H1 2016 38 Number of Products by Stage and Mechanis m of Action, H1 2016 40 Number of Products by Stage and Route of Adminis tration, H1 2016 42 Number of Products by Stage and Molecule Type, H1 2016 44 Lupus Nephritis Therapeutics - Recent Pipeline Updates , H1 2016 90 Lupus Nephritis - Dormant Projects , H1 2016 124 Lupus Nephritis - Dormant Projects (Contd..1), H1 2016 125 Lupus Nephritis - Dis continued Products , H1 2016 126 Lis t of Figures Number of Products under Development for Lupus Nephritis , H1 2016 10 Number of Products under Development for Lupus Nephritis - Comparative Analys is , H1 2016 11 Number of Products under Development by Companies , H1 2016 12 Number of Products under Inves tigation by Univers ities /Ins titutes , H1 2016 13 Comparative Analys is by Clinical Stage Development, H1 2016 15 Comparative Analys is by Early Stage Products , H1 2016 16 As s es s ment by Monotherapy Products , H1 2016 36 Number of Products by Top 10 Targets , H1 2016 37 Number of Products by Stage and Top 10 Targets , H1 2016 37 Number of Products by Top 10 Mechanis m of Actions , H1 2016 39 Number of Products by Stage and Top 10 Mechanis m of Actions , H1 2016 39 Number of Products by Routes of Adminis tration, H1 2016 41 Number of Products by Stage and Routes of Adminis tration, H1 2016 41 Number of Products by Molecule Types , H1 2016 43 Number of Products by Stage and Top 10 Molecule Types , H1 2016 43

wis eguyreports .com / Phone (US) + 1-646-845-9349 (UK) +44 208 133 9349